The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study
| Autor: | Jindrich Finek, Vaclav Liska, Jana Kulhankova, Tomas Buchler, Zbynek Bortlicek, Lubos Holubec, Ondrej Fiala, Ondrej Topolcan, Vit Martin Matejka |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Pathology Bevacizumab CA-19-9 Antigen Colorectal cancer Tissue Polypeptide Antigen medicine.medical_treatment Thymidine Kinase Cohort Studies Carcinoembryonic antigen Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Biomarkers Tumor Humans Pharmacology (medical) Neoplasm Metastasis Aged Retrospective Studies Aged 80 and over biology business.industry Hazard ratio Retrospective cohort study Middle Aged medicine.disease Tissue Polypeptide Specific Antigen Carcinoembryonic Antigen Radiation therapy biology.protein Female business Colorectal Neoplasms Peptides medicine.drug |
| Zdroj: | Targeted oncology. 10(4) |
| ISSN: | 1776-260X |
| Popis: | The aim of our retrospective study was to analyze the association of selected tumor markers (TMs) including serum carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), thymidine kinase, and tissue polypeptide specific antigen with outcomes in patients with metastatic colorectal cancer (mCRC) treated with bevacizumab. There is an increasing body of evidence from retrospective/observational studies that some serum TMs may be predictive of effect of targeted therapies in mCRC. In our study, the cohort included 152 patients treated with bevacizumab-based therapy between years 2005 and 2014 at Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen. Serum samples for measurement of TMs were collected within 1 month before the initiation of bevacizumab-based treatment. In multivariate Cox analysis that included serum tumor markers and clinical baseline parameters, the number of metastatic sites (hazard ratio [HR] = 2.00, p = 0.001) and CEA levels (HR = 2.80, p < 0.001) were significantly associated with progression-free survival, whereas CA 19-9 levels (HR = 2.25, p = 0.008) were the only studied parameter associated with overall survival. Quantification of serum CEA and CA 19-9 is simple and readily available, and their candidate prognostic importance in the setting of antiangiogenesis therapy deserves to be studied in prospective trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink